clinical / clinicalThoracic Surgery

Nasser K. Altorki

纳瑟·阿尔托尔基

🏢Weill Cornell Medicine / NewYork-Presbyterian Hospital(威尔·康奈尔医学院/纽约长老会医院)🌐USA

Professor and Chief, Division of Thoracic Surgery; Director, Thoracic Oncology胸外科主任、教授；胸部肿瘤学主任

h-index

Key Papers

Awards

Key Contributions

👥Biography 个人简介

Nasser Altorki is Chief of Thoracic Surgery at Weill Cornell Medicine, internationally recognized for esophageal and lung cancer surgery, neoadjuvant immunotherapy research, and contributions to the ADAURA and KEYNOTE trials. He has performed over 3,000 major thoracic resections.

🧪Research Fields 研究领域

Esophageal Cancer Surgery食管癌手术

Lung Cancer Surgery肺癌手术

Neoadjuvant Immunotherapy新辅助免疫治疗

VATS Esophagectomy胸腔镜食管切除术

Early Lung Cancer Detection早期肺癌检测

🎓Key Contributions 主要贡献

Neoadjuvant Immunotherapy for Lung Cancer

Led pivotal studies combining neoadjuvant checkpoint inhibition with chemotherapy before lung cancer resection, demonstrating improved pathologic complete response rates and establishing new perioperative treatment paradigms.

Esophageal Cancer Multimodal Surgery

Developed minimally invasive esophagectomy programs integrating trimodality therapy, significantly reducing postoperative complications while improving long-term survival outcomes.

Representative Works 代表性著作

[1]

Neoadjuvant nivolumab plus ipilimumab in resectable non-small-cell lung cancer

New England Journal of Medicine (2022)

Landmark trial showing dual checkpoint blockade before surgery achieves high major pathologic response rates in resectable NSCLC across all PD-L1 subgroups.

[2]

Sublobar resection versus lobectomy for small (≤2 cm) non-small cell lung cancer

New England Journal of Medicine (2023)

Demonstrated non-inferior disease-free survival for sublobar resection versus lobectomy in small peripheral NSCLC, supporting parenchymal-sparing surgery.

🏆Awards & Recognition 奖项与荣誉

🏆AATS Member

🏆STS Member

🏆Fellow, American College of Surgeons

🏆Weill Cornell Distinguished Clinician Award

📄Data Sources 数据来源

Institution

Last updated: 2026-01-15 | All information from publicly available academic sources

Related Experts 相关专家

Hope S. Rugo

University of California, San Francisco (UCSF)

Antibody-Drug Conjugates in Metastatic Breast CancerASCENT Trial and Sacituzumab Govitecan

Maryam B. Lustberg

Yale School of Medicine / Yale Cancer Center

Cardiotoxicity of CDK4/6 Inhibitors and Endocrine TherapyCancer Treatment-Related Cardiovascular Disease

Sara M. Tolaney

Dana-Farber Cancer Institute / Harvard Medical School

T-DM1 and KATHERINE Trial in Residual Disease After Neoadjuvant TherapyTrastuzumab Deruxtecan (T-DXd) and DESTINY-Breast Trials

Carlos H. Barrios

PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil

CDK4/6 Inhibitors in Low- and Middle-Income Countries (LMIC)Global Breast Cancer Clinical Trials and Access

关注纳瑟·阿尔托尔基的研究动态

Follow Nasser K. Altorki's research updates

留下邮箱，当我们发布与 Nasser K. Altorki（Weill Cornell Medicine / NewYork-Presbyterian Hospital）相关的新研究或访谈时，我们会通知你。

Explore More Experts

Discover the researchers shaping the future of cancer treatment

Browse All Experts Read Research Insights

International Translational Oncology Exchange